Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider

The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access. North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.

09/25/2026, 8:30 AM • GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

HUTCHMED announced that two Phase III studies evaluating the savolitinib and osimertinib combination for non-small cell lung cancer will be presented at ESMO Congress 2026 in Madrid. The SAFFRON global study and SANOVO China study both demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared to chemotherapy and osimertinib monotherapy, respectively. The all-oral, chemo-free combination has been selected for high-profile oral presentations including a Presidential Symposium.

09/23/2026, 8:00 PM • GlobeNewswire

AI in Drug Discovery Market Poised for Rapid Growth Through 2035, Fueled by Faster R&D, Precision Medicine and Rising Biopharma Investment

The global AI in drug discovery market is projected to grow from USD 2.55 billion in 2025 to USD 31.79 billion by 2035, expanding at a 28.70% CAGR. Lead optimization and oncology applications are driving adoption, with pharmaceutical companies and biotech firms leading investment. Strategic partnerships and funding rounds, including Isomorphic Labs' $600 million raise and Takeda's $1.7 billion collaboration with Iambic Therapeutics, are accelerating market growth.

09/23/2026, 5:59 AM • GlobeNewswire

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

The psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.

09/21/2026, 1:00 PM • GlobeNewswire

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

09/17/2026, 6:49 AM • GlobeNewswire

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand

The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.

09/16/2026, 4:55 AM • GlobeNewswire

Hummingbird Bioscience Appoints Dr. James Garner as President

Hummingbird Bioscience announced the appointment of Dr. James Garner as President. Garner brings over two decades of experience in drug development and commercialization from roles at Biogen, Takeda, and Sanofi, with a track record of overseeing 30+ product approvals. He previously served as CEO of Percheron Therapeutics and Kazia Therapeutics.

09/15/2026, 5:00 AM • GlobeNewswire

Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider

The global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma supply dependency and a 100% U.S. tariff on imported IVIG products implemented in October 2025 pose significant constraints. North America leads the market, while Asia-Pacific shows the fastest growth.

09/09/2026, 8:30 PM • GlobeNewswire

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider

The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.

09/07/2026, 6:52 AM • GlobeNewswire

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been recognized in The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The recognition highlights the company's achievements in advancing innovative cancer therapies, including the commercialization of olverembatinib and lisaftoclax, with multiple global Phase III clinical trials underway.

07/26/2026, 7:30 PM • GlobeNewswire

[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global botulinum toxin in urology market is projected to grow from USD 1.1 billion in 2025 to USD 1.98 billion by 2035, at a CAGR of 6.08%. Growth is driven by increasing prevalence of urological disorders, aging populations, preference for minimally invasive treatments, and advancements in injection techniques. OnabotulinumtoxinA (Botox) leads the market, with overactive bladder being the largest application segment.

07/22/2026, 2:00 PM • GlobeNewswire

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes

ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as a benchmarking resource for biopharma dealmakers.

07/17/2026, 6:48 AM • GlobeNewswire

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med

Takeda Pharmaceutical's AI-developed drug zasocitinib demonstrated statistical superiority over Bristol-Myers Squibb's deucravacitinib in a Phase 3 head-to-head trial for plaque psoriasis treatment. Zasocitinib achieved over 35% complete skin clearance (PASI 100) at week 16, more than 2.5 times the response rate of the competitor drug. The company plans to submit a New Drug Application to the FDA this fiscal year, with peak annual sales potential of $3-6 billion.

06/11/2026, 1:12 PM • Benzinga

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

Ascentage Pharma presented updated clinical data at ASCO 2026 showing olverembatinib achieved a 91.3% complete cytogenetic response rate and 60.9% major molecular response rate at cycle 24 in CML-CP patients as second-line therapy. The drug demonstrated a stable safety profile with no new safety signals, supporting its potential role in treating patients who failed first-line TKI therapy.

05/31/2026, 7:30 PM • GlobeNewswire